Mebendazole plus lomustine or temozolomide in patients with recurrent glioblastoma: A randomised open-label phase II trial

Mebendazole plus lomustine or temozolomide in patients with recurrent glioblastoma: A randomised open-label phase II trial

Summary: Background: Recurrent glioblastoma (GBM) has dismal outcomes and limited treatment options. Mebendazole (MBZ) has activity in glioma both in-vivo and in-vitro, and is well tolerated in combination with lomustine (CCNU) and temozolomide (TMZ). In this study, we sought to determine whether t...

Full description

Bibliographic Details
Main Authors: Vijay M. Patil, Nandini Menon, Abhishek Chatterjee, Raees Tonse, Amit Choudhari, Abhishek Mahajan, Ameya D. Puranik, Sridhar Epari, Monica Jadhav, Shruti Pathak, Zoya Peelay, Rutuja Walavalkar, Hemanth K. Muthuluri, Madala Ravi Krishna, Arun Chandrasekharan, Nikhil Pande, Tejpal Gupta, Shripad Banavali, Rakesh Jalali
Format: Article
Language:English
Published: Elsevier 2022-07-01
Series:EClinicalMedicine
Subjects:
Mebendazole
Glioblastoma
Recurrent
Salvage
CCNU
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537022001791

Internet

http://www.sciencedirect.com/science/article/pii/S2589537022001791

Similar Items